Quotables
"Rail travel at high speeds is not possible because passengers, unable to breathe, would die of asphyxia."
Dionysius Lardner, Professor of Natural Philosophy and Astronomy at University College, London ; 1830
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8026245 | HIV replication inhibiting purine derivatives The present invention relates to the use of a compound of formula (I) for the manufacture of a medicament for the prevention or the treatment of HIV infection wherein the compound of formula (I) is a compound of formula a N... | 09/27/2011 |
| 7727995 | Antiherpes drug combinations Composition and methods are disclosed that include a synergistic combination of an inhibitor of Herpes simplex virus thymidine kinase, and an antiherpes substance. ... | 06/01/2010 |
| 7432274 | Acyclic nucleoside derivatives Methods and novel intermediates for the preparation of and the treatment with acyclic nucleoside derivatives of the formula: where one of R1 and R2 is an amino acid acyl group ... | 10/07/2008 |
| 7393855 | 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and pyrimidines as antiviral agents Compounds which are active against viruses have the following formulas: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (... | 07/01/2008 |
| 7335654 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/26/2008 |
| 7273864 | Compositions and methods for inducing osteogenesis The present invention provides compositions and methods for differentiating and transdifferentiating mammalian cells into cells of an osteoblast lineage, using compounds of the following formula: wherein R4 ... | 09/25/2007 |
| 7256196 | Purine cytokine inhibitors The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions c... | 08/14/2007 |
| 7238700 | Aadenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R1 is... | 07/03/2007 |
| 7217702 | Selective antagonists of A2A adenosine receptors Selective antagonists of A2A adenosine receptors like those of formula I are provided, wherein Y forms a ring. The novel A2A blockers are useful for the treatment of Parkinsons disease and o... | 05/15/2007 |
| 7189730 | Aadenosine receptor antagonists Disclosed are novel A2A adenosine receptor antagonists of the formula: wherein: R1 is optionally substituted aryl or optionally substituted heteroaryl; | 03/13/2007 |
| 7183268 | 2-amino-9-[(2-hydroxymethyl) cyclopropylidenemethyl] purine antiviral agents Compounds which are active against viruses have the following Formulas: wherein B is 2-aminopurine-9-yl, which may be unsubstituted or substituted in the 6 position with NHR1, ... | 02/27/2007 |
| 7157465 | Adenine derivatives This invention relates to an adenine derivative, a tautomer thereof, or a pharmaceutically acceptable salt thereof represented by general formula (I): wherein X represents NR3 (wherein R3 re... | 01/02/2007 |
| 7157449 | Medicament for the treatment of diseases caused by parasitic protozoa The present invention relates to the use of an inhibitor of CTP synthetase, such as a glutamine analogue, and a substance capable of suppressing toxic effects thereof in vivo, in the manufacture of a medicament for the treatment of a disease caused by a parasitic pr... | 01/02/2007 |
| 7138402 | Pyrrolopyrimidines and related analogs as HSP90-inhibitors The present invention provides compounds represented by Formula I. R0 is selected from hydrogen, halogen, lower alkyl, —SR8, —OR8, —CN, and —NHR8, R1 is halogen, or lower alkyl; R2 is —NHR | 11/21/2006 |
| 7109341 | Therapeutic amides The invention provides compounds of the formula: wherein A, X, Y, and Z are as defined in the specification. The compounds are effective anti-tumor agents. The invention also provides pharmaceutical compositions ... | 09/19/2006 |
| 7105666 | Synthesis of purine derivatives The present invention provides a method for producing 2-, 6-, 8- and 9-substituted purine compounds from 4,6-dihalo-5-nitro-2-alkyl-pyrimidine compounds in solution or by solid phase techniques. The present process provides for the sequential introduction of amine s... | 09/12/2006 |
| 7091346 | Purine derivatives and processes for their preparation 2-Amino-6-anilino-purine derivatives of the formula 1 in which the symbols are as defined in claim 1 are described. These compounds inhibit p34cdc2/cyclin Bcdc13 kinase and can be us... | 08/15/2006 |
| 7087589 | Methanocarba cycloakyl nucleoside analogues The present invention provides novel nucleoside and nucleotide derivatives that are useful agonists or antagonists of P1 or P2 receptors. For example, the present invention provides a compound of formula A-M, wherein A is modified adenine or uracil and M is a constr... | 08/08/2006 |
| 7045525 | Use of (R)-peniciclovir triphosphate for the manufacture of a medicament for the treatment of viral diseases A method of treatment of: i) HIV-1 infections in mammals, including humans; or ii) HBV infections in mammals, including humans; which method comprises the administration to the human in need of such treatment, an effective amount of the (R)-enantiomer of the triphos... | 05/16/2006 |
| 7034016 | 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives of formula (I): or a pharmaceutically acceptable salt thereof processes for their preparation, pharmaceutical compositions containing them and their use... | 04/25/2006 |
| 7022710 | A1 adenosine receptor antagonists Disclosed are novel methods of antagonizing the A1 adenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula: wherein R... | 04/04/2006 |
| 7008948 | Fused pyrimidyl pyrazole compounds useful as protein kinase inhibitors This invention describes novel pyrazole compounds of formula IV: wherein Ring D is a 5-7 membered monocyclic ring or 8-10 membered bicyclic ring selected from aryl, heteroaryl, heterocyclyl or carbocyclyl; Rx | 03/07/2006 |
| 6974815 | Hexahydro-benzimidazolone compounds useful as anti-inflammatory agents The present invention is directed to compounds having the formula (I): useful in treating inflammatory and immune diseases, in which K is O or S; Q is —C(═O)— or optionally substituted C1-4alkylene; Ar... | 12/13/2005 |
| 6969720 | Biaryl substituted purine derivatives as potent antiproliferative agents The compounds of the present invention are 2,6,9-trisubstituted purine derivatives which are inhibitors of cyclin/cdk complexes. The compounds of the current invention also are potent inhibitors of human cellular proliferation. As such, the compounds of the present ... | 11/29/2005 |
| 6958344 | Pyrimidine compounds and their use as modulators of chemokine receptor activity The invention provides certain heterocyclic compounds, processes, and intermediates used in their preparation, pharmaceutical compositions containing them and their use in therapy; in formula (I), A is a group of formula (a) or (b). | 10/25/2005 |
| 6926763 | Purine and isosteric antibacterial compounds The invention features compounds of the formula: or a pharmaceutically acceptable salt thereof, wherein A is CR2 and B is N; wherein n is 0-3; wherein R1 is (CH2)m—{(G) | 08/09/2005 |
| 6924271 | 3-β-D-ribofuranosylthiazolo[4-5-d]pyridimine nucleosides and uses thereof The invention is directed to 3-β-D-ribofuranosylthiazolo[4,5-d]pyridimine nucleosides and pharmaceutical compositions containing such compounds that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compou... | 08/02/2005 |
| 6911460 | Antiviral agents and methods of treating viral infections The present invention relates to methods of treating viral or fungal infections using 3-aminopyridine-2-carboxyaldehyde thiosemicarbazone (3-AP) and 3-amino-4-methylpyridine-2-carboxaldehyde thiosemicarbazone (3-AMP) and its prodrug forms and to pharmaceutical compo... | 06/28/2005 |
| 6790841 | 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of 6-aminopurine (adenine), 2,6-diaminopu... | 09/14/2004 |
| 6770651 | A2B adenosine receptor antagonists Disclosed are novel A2B adenosine receptor antagonists of Formula I: A compound of the formula: wherein: R1 is optionally substituted alkyl or a group —Y—Z, in which Y is a covalent bond ... | 08/03/2004 |
| 6734187 | Purine derivatives and medicaments comprising the same as active ingredient Purine derivatives represented by the following formula and salts thereof: wherein R1 represents a C1-C4 alkyl group or difluoromethyl group; R2 represents tetrahydrofuranyl gr... | 05/11/2004 |
| 6620796 | Combinatorial library synthesis and pharmaceutically active compounds produced thereby The invention provides new methods for synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and a... | 09/16/2003 |
| 6589950 | Purine derivatives inhibitors of tyrosine protein kinase SYK Disclosed are compounds of the formula ##STR1## in free or salt form, wherein X, R1, R2, R3, and R4 are as defined in the specification, their preparation and their use as pharmaceuticals, particularly for the t... | 07/08/2003 |
| 6511984 | Neuropeptide Y antagonists Compounds of the formula ##STR1## wherein X is NR4 R5, Y is selected from C1 -C6 alkyl; alkoxyalkyl, C2 -C6 alkenyl; C2 -C6 alkynyl, alkoxy, aryl, or heteroaryl, or NR... | 01/28/2003 |
| 6440979 | Aryl isoguanines Disclosed are compounds having formula (II): ##STR1## wherein: Q3, Q6a, Q6b and Q8 are independently a bond, C1-8 alkylene, C2-8 alkenylene and C2-8 alkynylene, and R3... | 08/27/2002 |
| 6417180 | Zinc finger-reactive antimicrobial compounds The invention relates to antimicrobial compounds which interact with zinc in a zinc finger of a bacterial DNA polymerase, methods of screening for such compounds, and methods of using such compounds to inhibit polymerase activity or bacterial growth.... | 07/09/2002 |
| 6376501 | Type 2 helper T cell-selective immune response suppressors The present invention relates to a type 2 helper T cell-selective immune response inhibitor, an immune response regulator and an anti-allergic agent, individually comprising, as an active ingredient, a purine derivative represented by General Formula (I):... | 04/23/2002 |
| 6352991 | 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents Compounds which are active against viruses have the following Formulas: ##STR1## wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of 6-aminopurine (adenine), 2,6-diaminopurine, 2-amino-6-azidopurin... | 03/05/2002 |
| 6319928 | Purine derivatives having phosphodiesterase IV inhibition activity A compound of the formula: ##STR1## wherein R2 is O or S; R3, R6a and R8 are the same or different and each represent a C1-8 alkyl which is unbranched or branched and unsubstituted or substituted with... | 11/20/2001 |
| 6303618 | Cyclin dependent kinase inhibiting purine derivatives Method of treating a tumour or other cell proliferation disorder which comprises administering an effective amount of a purine compound which inhibits cyclic dependent kinase activity. Novel purine compounds and pharmaceutical compositions are also disclo... | 10/16/2001 |
